Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 188

Similar articles for PubMed (Select 12538400)

1.

Dopamine release during sequential finger movements in health and Parkinson's disease: a PET study.

Goerendt IK, Messa C, Lawrence AD, Grasby PM, Piccini P, Brooks DJ; PET study.

Brain. 2003 Feb;126(Pt 2):312-25.

2.

Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET.

Tedroff J, Pedersen M, Aquilonius SM, Hartvig P, Jacobsson G, Långström B.

Neurology. 1996 May;46(5):1430-6.

PMID:
8628494
3.

Upregulation of putaminal dopamine D2 receptors in early Parkinson's disease: a comparative PET study with [11C] raclopride and [11C]N-methylspiperone.

Kaasinen V, Ruottinen HM, Någren K, Lehikoinen P, Oikonen V, Rinne JO.

J Nucl Med. 2000 Jan;41(1):65-70.

4.

Chronic subthalamic nucleus stimulation and striatal D2 dopamine receptors in Parkinson's disease--A [(11)C]-raclopride PET study.

Thobois S, Fraix V, Savasta M, Costes N, Pollak P, Mertens P, Koudsie A, Le Bars D, Benabid AL, Broussolle E.

J Neurol. 2003 Oct;250(10):1219-23.

PMID:
14586606
5.

Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: a PET study with [11C]raclopride.

Rinne JO, Laihinen A, Ruottinen H, Ruotsalainen U, Någren K, Lehikoinen P, Oikonen V, Rinne UK.

J Neurol Sci. 1995 Oct;132(2):156-61.

PMID:
8543941
6.

Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias.

de la Fuente-Fernández R, Sossi V, Huang Z, Furtado S, Lu JQ, Calne DB, Ruth TJ, Stoessl AJ.

Brain. 2004 Dec;127(Pt 12):2747-54. Epub 2004 Aug 25.

7.
8.

Imaging in Parkinson's disease: the role of monoamines in behavior.

Brooks DJ, Piccini P.

Biol Psychiatry. 2006 May 15;59(10):908-18. Epub 2006 Apr 11. Review.

PMID:
16581032
9.

Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naive Parkinson's disease.

Boileau I, Guttman M, Rusjan P, Adams JR, Houle S, Tong J, Hornykiewicz O, Furukawa Y, Wilson AA, Kapur S, Kish SJ.

Brain. 2009 May;132(Pt 5):1366-75. doi: 10.1093/brain/awn337. Epub 2009 Jan 19.

10.

The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease.

Leenders KL, Salmon EP, Tyrrell P, Perani D, Brooks DJ, Sager H, Jones T, Marsden CD, Frackowiak RS.

Arch Neurol. 1990 Dec;47(12):1290-8.

PMID:
2123623
11.

Changes in dopamine availability in the nigrostriatal and mesocortical dopaminergic systems by gait in Parkinson's disease.

Ouchi Y, Kanno T, Okada H, Yoshikawa E, Futatsubashi M, Nobezawa S, Torizuka T, Tanaka K.

Brain. 2001 Apr;124(Pt 4):784-92.

12.

Effect of simple motor performance on regional dopamine release in the striatum in Parkinson disease patients and healthy subjects: a positron emission tomography study.

Ouchi Y, Yoshikawa E, Futatsubashi M, Okada H, Torizuka T, Sakamoto M.

J Cereb Blood Flow Metab. 2002 Jun;22(6):746-52.

13.

Stimulation of the subthalamic nucleus in Parkinson's disease does not produce striatal dopamine release.

Abosch A, Kapur S, Lang AE, Hussey D, Sime E, Miyasaki J, Houle S, Lozano AM.

Neurosurgery. 2003 Nov;53(5):1095-102; discussion 1102-5.

PMID:
14580276
14.

Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease.

Antonini A, Leenders KL, Vontobel P, Maguire RP, Missimer J, Psylla M, Günther I.

Brain. 1997 Dec;120 ( Pt 12):2187-95.

15.

Endogenous dopamine release induced by repetitive transcranial magnetic stimulation over the primary motor cortex: an [11C]raclopride positron emission tomography study in anesthetized macaque monkeys.

Ohnishi T, Hayashi T, Okabe S, Nonaka I, Matsuda H, Iida H, Imabayashi E, Watabe H, Miyake Y, Ogawa M, Teramoto N, Ohta Y, Ejima N, Sawada T, Ugawa Y.

Biol Psychiatry. 2004 Mar 1;55(5):484-9.

PMID:
15023576
16.

A PET study of sequential finger movements of varying length in patients with Parkinson's disease.

Catalan MJ, Ishii K, Honda M, Samii A, Hallett M.

Brain. 1999 Mar;122 ( Pt 3):483-95.

17.

Oral methylphenidate fails to elicit significant changes in extracellular putaminal dopamine levels in Parkinson's disease patients: positron emission tomographic studies.

Koochesfahani KM, de la Fuente-Fernández R, Sossi V, Schulzer M, Yatham LN, Ruth TJ, Blinder S, Stoessl AJ.

Mov Disord. 2006 Jul;21(7):970-5.

PMID:
16570297
18.

Endogenous dopamine release after pharmacological challenges in Parkinson's disease.

Piccini P, Pavese N, Brooks DJ.

Ann Neurol. 2003 May;53(5):647-53.

PMID:
12730999
19.

New perspectives on neurochemical effects of amantadine in the brain of parkinsonian patients: a PET - [(11)C]raclopride study.

Moresco RM, Volonte MA, Messa C, Gobbo C, Galli L, Carpinelli A, Rizzo G, Panzacchi A, Franceschi M, Fazio F.

J Neural Transm. 2002 Oct;109(10):1265-74.

PMID:
12373560
20.

Caudate nucleus: influence of dopaminergic input on sequence learning and brain activation in Parkinsonism.

Carbon M, Ma Y, Barnes A, Dhawan V, Chaly T, Ghilardi MF, Eidelberg D.

Neuroimage. 2004 Apr;21(4):1497-507.

PMID:
15050574
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk